JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB6854

Goat Anti-Human IgG H&L (FITC)

Be the first to review this product! Submit a review

|

(13 Publications)

Goat Anti-Human IgG H&L (FITC) is a secondary antibody with a maximum absorption wavelength of 495nm and a maximum emission wavelength of 519nm. Ideal for fluorescent cell and tissue imaging. Suitable for Western blot, IHC, ICC/IF, Flow Cytometry, ELISA and more.

View Alternative Names

Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig gamma-1 chain C region KOL, Ig gamma-1 chain C region NIE, IGHG1, Immunoglobulin heavy constant gamma 4, Ig gamma-4 chain C region, IGHG4, Immunoglobulin heavy constant gamma 3, HDC, Heavy chain disease protein, Ig gamma-3 chain C region, IGHG3, Immunoglobulin heavy constant gamma 2, Ig gamma-2 chain C region, Ig gamma-2 chain C region DOT, Ig gamma-2 chain C region TIL, Ig gamma-2 chain C region ZIE, IGHG2

2 Images
Western blot - Goat Anti-Human IgG H&L (FITC) (AB6854)
  • WB

Supplier Data

Western blot - Goat Anti-Human IgG H&L (FITC) (AB6854)

Western blot analysis of ab6854 used as a secondary antibody at 1/1000 dilution for 60 min at RT.

All lanes:

Human IgG at 50 ng

Secondary

All lanes:

Western blot - Goat Anti-Human IgG H&L (FITC) (ab6854) at 1/1000 dilution

false

Dot Blot - Goat Anti-Human IgG H&L (FITC) (AB6854)
  • Dot

Supplier Data

Dot Blot - Goat Anti-Human IgG H&L (FITC) (AB6854)

Dot blot analysis of ab6854.

Key facts

Host species

Goat

Target species

Human

Target isotype

IgG

Target specificity

Heavy & Light chains

Minimal cross-reactivity
Pre-adsorbed

No

Conjugation

FITC

Excitation/Emission

Ex: 495nm, Em: 519nm

Applications

ELISA, Flow Cyt, WB, IM, ICC/IF, Dot, IHC-P, IHC-Fr

applications

Clonality

Polyclonal

Isotype

IgG

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Flow Cyt": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"", "notes":"<p></p>" }, "IHC-Fr": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"", "notes":"<p></p>" }, "IHC-P": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"", "notes":"<p></p>" }, "IM": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"", "notes":"<p></p>" }, "ELISA": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"1/10000 - 1/50000", "notes":"<p></p>" }, "ICC/IF": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"1/1000 - 1/5000", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "Dot": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

This antibody reacts with the heavy and light chains of Human IgG

Fluorochrome chart- a complete quick and easy guide to help you select the most appropriate fluorochromes for your next experiment.

When it comes to advancing your immunohistochemistry (IHC) research, Abcam offers comprehensive suite of IHC kits and secondary antibodies, designed to deliver precise and reliable results.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification
Purification notes
This product was prepared from monospecific antiserum by immunoaffinity chromatography using Human IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities.
Storage buffer
Preservative: 0.01% Sodium azide Constituents: 1% BSA, 0.88% Sodium chloride, 0.164% Sodium phosphate
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C

Product protocols

Target data

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellular receptors (via the antigen-binding region) and eliciting effector mechanisms that lead to pathogen neutralization (via the constant region) (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The antigen-binding region is formed by the variable domain of one heavy chain paired with the variable domain of its associated light chain. Each Ig molecule has two antigen-binding sites with remarkable affinity for a particular antigen due to V-(D)-J rearrangement, somatic hypermutations and affinity maturation of the variable domains upon antigen exposure (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region defines the Ig isotype that perform distinct sets of effector functions. B cells diversify and rearrange their Ig constant regions through class-switch recombination, a process by which the constant region is switched from one Ig isotype to another, namely from IgM and IgD to IgG, IgA and IgE (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region of Ig gamma-1 (IgG1) isotype interacts (via the fragment crystallizable, Fc) with receptors on innate immune cells and the complement system to mediate humoral effector functions, including antibody-dependent cellular cytotoxicity or phagocytosis, complement-dependent cytotoxicity and inflammatory responses.
See full target information IGHG1

Additional targets

IGHG4,IGHG3,IGHG2

Publications (13)

Recent publications for all applications. Explore the full list and refine your search

Journal for immunotherapy of cancer 12: PubMed39357981

2024

Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses.

Applications

Unspecified application

Species

Unspecified reactive species

Yijun Dong,Zongliang Zhang,Siyuan Luan,Meijun Zheng,Zeng Wang,Yongdong Chen,Xiaoting Chen,Aiping Tong,Hui Yang

Cell discovery 10:99 PubMed39349449

2024

Developing an erythrocyte‒MHC-I conjugate for cancer treatment.

Applications

Unspecified application

Species

Unspecified reactive species

Yuehua Liu,Xiaoqian Nie,Xingyun Yao,Huafeng Shou,Yang Yuan,Yun Ge,Xiangmin Tong,Hsiang-Ying Lee,Xiaofei Gao

Cell reports. Medicine 5:101590 PubMed38843844

2024

Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement.

Applications

Unspecified application

Species

Unspecified reactive species

Yunfeng Pan,Qi Xue,Yi Yang,Tao Shi,Hanbing Wang,Xueru Song,Yuting Luo,Wenqi Liu,Shiji Ren,Yiran Cai,Yang Nie,Zhentao Song,Baorui Liu,Jie P Li,Jia Wei

Experimental and therapeutic medicine 27:254 PubMed38682116

2024

Preparation and evaluation of the PD0721‑DOX antibody‑drug conjugate targeting EGFRvIII to inhibit glioblastoma.

Applications

Unspecified application

Species

Unspecified reactive species

Minmin Hu,Hong Liu,Yubing Zhang,Dingyan Lu,Lin Zheng,Yonglin Wang,Shuaishuai Chen,Ting Liu

Journal of dental sciences 18:1008-1015 PubMed37404619

2023

Clinical, histological and direct immunofluorescence features in oral mucosal patches striae diseases with malignant potential.

Applications

Unspecified application

Species

Unspecified reactive species

Chun-Lei Li,Xiao-Meng Ren,Xin Fang,Hai-Yan Luo,Hong Hua

FEBS open bio 12:1797-1813 PubMed35945910

2022

Mammaglobin 1 mediates progression of trastuzumab-resistant breast cancer cells through regulation of cyclins and NF-κB.

Applications

Unspecified application

Species

Unspecified reactive species

Ratih Kusumastuti,Yuji Kumagai,Seiichiro Ishihara,Atsushi Enomoto,Takashi Murakami,Motoaki Yasuda,Hisashi Haga

International journal of biological sciences 18:1363-1380 PubMed35280694

2022

Cancer-associated adipocytes promote the invasion and metastasis in breast cancer through LIF/CXCLs positive feedback loop.

Applications

Unspecified application

Species

Unspecified reactive species

Chong Zhou,Xi He,Chang Tong,Honghui Li,Caifeng Xie,Yudong Wu,Lieliang Wang,Xiaohua Yan,Daya Luo,Yunpeng Tang,Zhongman Cheng,Xiangyang Xiong

Oncology letters 21:400 PubMed33777223

2021

Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells.

Applications

Unspecified application

Species

Unspecified reactive species

Chao Wang,Lingfei Wang,Beibei Liang,Bo Zhou,Yu Sun,Yanchun Meng,Jian Dong,Lin Chen,Bohua Li

The Journal of infectious diseases 223:1313-1321 PubMed33605423

2021

Susceptibility and Attenuated Transmissibility of SARS-CoV-2 in Domestic Cats.

Applications

Unspecified application

Species

Unspecified reactive species

Linlin Bao,Zhiqi Song,Jing Xue,Hong Gao,Jiangning Liu,Jie Wang,Qian Guo,Binbin Zhao,Yajin Qu,Feifei Qi,Shuran Gong,Mingya Liu,Qi Lv,Dan Li,Yunlin Han,Wenjie Zhao,Shoulong Deng,Yunpeng Liu,Zhiguang Xiang,Bochao Yang,Wei Deng,Haisheng Yu,Zhe Cong,Qiang Wei,Jianguo Xu,George F Gao,Chuan Qin

Frontiers in physiology 11:606967 PubMed33603676

2021

MiR-143-3p Inhibits Osteogenic Differentiation of Human Periodontal Ligament Cells by Targeting KLF5 and Inactivating the Wnt/β-Catenin Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Kaixin Wangzhou,Zhiying Lai,Zishao Lu,Wanren Fu,Cheng Liu,Zhengeng Liang,Yi Tan,Conghui Li,Chunbo Hao
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com